EORTC 2022
Interviews and expert commentary from EORTC 2022 — study authors and key opinion leaders discuss the findings and their clinical implications.
AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy
ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study
Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i
AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses
BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting
BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-